Investing in U.S. Healthcare: The Big and Small of It

March 13, 2025
You must provide your professional email address to view this content.

Although we are skeptical that a complete overhaul of the U.S. healthcare system is in the cards, policy momentum is clearly pushing for: greater focus on chronic disease, lower drug pricing and greater transparency, less government-backed insurance coverage, and more domestically produced health care goods. With these goalposts in place, we see “big” pharma and insurance most directly in the line of fire of U.S. policy changes and recommend that investors looking to capitalize on the defensive characteristics of the healthcare sector, where possible, avoid these companies. Similarly, wait for tariff clarity before increasing positions in healthcare equipment. Conversely, under-the-radar health names with attractive financials – United Therapeutics, Ipsen, Exelixis and Privia Health Group- are well-positioned to outperform.

Disclaimer / Securities Disclosure

The author(s) of this research note do (does) not personally hold a any position in any of the above-mentioned securities.
Nordis Capital (SMS’ sister company) does hold positions in Zimmer Biomet, Boston Scientific, Edwards Lifesciences and GE Healthcare in its funds.

DISCLAIMER
© Sustainable Market Strategies, a division of SMS Financial Technologies inc. Redistribution prohibited without prior consent. This report has been prepared by Sustainable Market Strategies mainly for distribution to market professionals and institutional investors. It should not be considered as investment advice or a recommendation to purchase any particular security, strategy, or investment product. References to specific securities and issuers are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed.